ClinicalTrials.gg
RecruitingNCT07361692ALGOSTIMUpdated Jun 18, 2026

Effectiveness of Transcranial Direct Current Stimulation (tDCS) in the Management of Complex Regional Pain Syndrome

An interventional study of transcranial direct current stimulation and Placebo in Complex Regional Pain Syndrome (CRPS), sponsored by Polyclinique de l'Europe. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Polyclinique de l'Europe · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Complex Regional Pain Syndromes with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Complex Regional Pain Syndromes · France.

Planned enrollment
8th of 13
32 · median 60
Started
2026
with 1 other
No phase
10 of 17
4 open now
Registered
16th of 17
by date

Among the 17 studies in Complex Regional Pain Syndromes with a site in France, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 16th registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

6 of the 17 studies in Complex Regional Pain Syndromes with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Complex Regional Pain Syndromes studies recruiting now, 19 (46%) set no upper age limit and 16 (39%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Complex Regional Pain Syndromes with a site in France, or all of them as a file.
02

Study summary

Transcranial direct current stimulation (tDCS) is a non-invasive therapy increasingly used in facilities treating patients with chronic pain. This complementary therapy has the advantage of being non-pharmacological, with transient and mild side effects, an excellent safety profile, and good efficacy in the contexts where it has been the subject of dedicated research: neuropathic pain, fibromyalgia, and visceral pain. Few studies have focused on the application of tDCS in the context of complex regional pain syndrome (CRPS), which is a common condition.

Read the detailed description

This protocol aims to compare a group receiving a tDCS protocol with a sham control group. The hypothesis of this study is that tDCS is effective in treating CRPS in terms of reducing pain and the functional and emotional consequences of pain.

The primary objective of the study is to evaluate the effectiveness of tDCS on pain in patients with CRPS (complex regional pain syndrome), measured by the numerical pain scale (EN), after one month of treatment and one month after the end of treatment, compared to the sham arm.

The secondary objectives are:

  • To assess anxiety and depression symptoms (HAD)
  • To assess the functional impact of pain (Concise Pain Questionnaire - QCD)
  • To assess central sensitization (Central Sensitization Inventory - CSI)
  • To identify adverse effects related to tDCS
03

Conditions studied

  • Complex Regional Pain Syndrome (CRPS)

Keywords

  • Transcranial direct current stimulation
  • Complex Regional Pain Syndrome
  • pain
  • quality of life
  • anxiety
  • central sensitization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major
  • Clinically active or active complex regional pain syndrome (CRPS) with positive Budapest criteria
  • Scintigraphy showing signs consistent with CRPS
  • Being affiliated with or a beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Algodystrophy no longer meeting the Budapest criteria
  • Relative to tDCS: psychosis (including treated psychosis), uncontrolled epilepsy, large scalp scar, intracerebral/intracranial metallic body
  • Pregnant or breastfeeding women
  • Minors
  • Persons under legal protection (guardianship, conservatorship, and protective supervision)
  • Persons deprived of their liberty by judicial or administrative order
  • Unwilling individuals who cannot give their consent or cannot return for scheduled visits according to the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Patient group receiving tDCS stimulation

    Progressive increase in stimulation intensity up to 2 mA, then continuation at a plateau for a total of 20 minutes, then a decrease in stimulation intensity for 30 seconds at the end of the session before an automatic stop.

    Other: transcranial direct current stimulation

  • Placebo comparator
    Patient group receiving tDCS placebo stimulation

    Control group : The stimulation intensity is gradually increased up to 2 mA for 1 minute, then decreased to zero stimulation. A further increase in stimulation is programmed 10 minutes after the start of stimulation.

    Other: Placebo

Interventions

  • Othertranscranial direct current stimulation

    progressive increase in stimulation intensity up to 2 mA, then continuation at a plateau for a total of 20 minutes, then a decrease in stimulation intensity for 30 seconds at the end of the session before an automatic stop.

  • OtherPlacebo

    The stimulation intensity is gradually increased up to 2 mA for 1 minute, then decreased to zero stimulation. A further increase in stimulation is programmed 10 minutes after the start of stimulation.

06

What researchers measure

Primary outcomes

  1. Analog Visual Scale

    Time frame: one month post treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 66 non-industry interventional studies with no phase under Complex Regional Pain Syndromes, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 14 months is below that.

Counting every sponsor, half of 67 studies reached it within 24 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07361692
Lead sponsor
Polyclinique de l'Europe
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Apr 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Valentin Billard
Contact
vbillard@vivalto-sante.com
02 51 16 16 16

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion